세계의 급성 신부전(ARF) 시장 : 출시 약품과 파이프라인 약품 평가, 임상시험, 경쟁 구도
Acute Renal Failure (ARF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
상품코드
:
1376901
리서치사
:
GlobalData
발행일
:
2023년 10월
페이지 정보
:
영문 68 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
개요
GlobalData ARF의 역학 예측에서는 16개국에서 2023년에 1,800만을 넘는 ARF의 발증이 예측됩니다.
현재 ARF의 치료제로 승인되고 있는 것은 소수이며, 대부분이 용질 캐리어 패밀리 12 멤버 1저해제에 속합니다.
ARF의 후기 파이프라인에는 단계 III에 있는 3개의 약제와 단계 II에 있는 9개의 약제가 포함됩니다. 어느 약제도 개발의 등록 전단계에는 없습니다.
과거 10년간 ARF의 단일 제제 시험은 주로 아시아태평양(25 시험)에서 시행되었으며, 북미(17 시험)가 그 뒤를 이었습니다.
파트너십은 전 세계의 ARF 분야에서 가장 현저한 거래의 유형이었습니다.
세계의 급성 신부전(ARF) 시장에 대해 조사분석했으며, 질환 상황, 출시 약품과 파이프라인 약품 평가, 현재와 향후 경쟁 구도 등을 제공하고 있습니다.
목차
제1장 서문
제2장 주요 조사 결과
제3장 질환 상황
제4장 출시 약품 평가
- 주요 출시 약품
- 개요 : 작용기서별
- 개요 : 투여 경로별
- 출시 약품 개요와 판매의 예측
제5장 가격결정과 상환 평가
제6장 파이프라인 약품 평가
- 단계 3 파이프라인 약품
- 개요 : 개발 단계별
- 개요 : 분자 유형별
- 개요 : 작용기서별
- 개요 : 투여 경로별
- 약품 고유 단계 이동 성공률(PTSR)과 승인 가능성(LoA)
- 치료 영역과 적응증 고유 PTSR과 LoA
제7장 임상시험 평가
- 과거의 개요
- 개요 : 단계별
- 개요 : 현황별
- 개요 : 진행중·계획중 시험 단계별
- 가상 컴포넌트를 사용한 시험
- 지역적 개요
- 단일국·다국간 시험 : 지역별
- 상위 20 스폰서와 내역 : 단계별
- 상위 20 스폰서와 내역 : 현황별
- 개요 : 엔드포인트 현황별
- 개요 : 인종/민족별
- 등록 데이터
- 시험 시설 상위 20개국
- 세계의 상위 20 시설
- 실현 가능성 분석 - 지역적 개요
- 실현 가능성 분석 - 벤치마크 모델
제8장 거래 상황
- 합병, 인수, 전략적 제휴 : 지역별
- 최근 합병, 인수, 전략적 제휴
제9장 상업적 평가
제10장 향후 시장 촉매
제11장 부록
KSA
영문 목차
Abstract
This reports provides a data-driven overview of the current and future competitive landscape in ARF therapeutics.
More than 18 million incident cases of ARF are anticipated in 2023 in the 16 countries covered in GlobalData's epidemiology forecast for ARF.
Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, most belonging to the solute carrier family 12 member 1 inhibitor.
The late-stage pipeline for ARF includes three drugs in Phase III and nine drugs in Phase II. None of the drugs are present at the pre-registration stage of development.
In the past 10 years, single-country trials for ARF were conducted mostly in Asia-Pacific (25 trials), followed by North America (17 trials).
Partnerships were the most prominent type of deal ventured in the ARF space globally.
Scope
GlobalData's ARF: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the ARF market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ARF market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Table of Contents
1 Preface
- 1.1 Contents
- 1.2 Report Scope
- 1.3 List of Tables and Figures
- 1.4 Abbreviations
2 Key Findings
3 Disease Landscape
- 3.1 Disease Overview
- 3.2 Epidemiology Overview
- 3.3 Treatment Overview
4 Marketed Drugs Assessment
- 4.1 Leading Marketed Drugs
- 4.2 Overview by Mechanism of Action
- 4.3 Overview by Route of Administration
- 4.4 Marketed Drugs Profiles and Sales Forecasts
5 Pricing and Reimbursement Assessment
- 5.1 Annual Therapy Cost
- 5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
- 6.1 Phase III Pipeline Drugs
- 6.2 Overview by Development Stage
- 6.3 Overview by Molecule Type
- 6.4 Overview by Mechanism of Action
- 6.5 Overview by Route of Administration
- 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
- 6.7 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
- 7.1 Historical Overview
- 7.2 Overview by Phase
- 7.3 Overview by Status
- 7.4 Overview by Phase for Ongoing and Planned Trials
- 7.5 Trials with Virtual Components
- 7.6 Geographic Overview
- 7.7 Single-Country and Multinational Trials by Region
- 7.8 Top 20 Sponsors with Breakdown by Phase
- 7.9 Top 20 Sponsors with Breakdown by Status
- 7.10 Overview by Endpoint Status
- 7.11 Overview by Race and Ethnicity
- 7.12 Enrollment Data
- 7.13 Top 20 countries for Trial Sites
- 7.14 Top 20 Sites Globally
- 7.15 Feasibility Analysis - Geographic Overview
- 7.16 Feasibility Analysis - Benchmark Models
8 Deals Landscape
- 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
- 8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
10 Future Market Catalysts
11 Appendix
- 11.1 Methodology
- 11.2 Methodology - Sales Forecast
- 11.3 Methodology - Pricing and Reimbursement
- 11.4 Methodology - PTSR and LoA Analysis
- 11.5 About the Authors
- 11.6 Contact Us
- 11.7 Disclaimer
관련자료
